PAPaolo Salvatore Lorenzo Aiello

Paolo Salvatore Lorenzo Aiello

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paolo Salvatore Lorenzo Aiello has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intraoperative nerve monitoring in thyroid and parathyroid surgery: a decade of Italian practice

    by R. Melcarne, G. Docimo, P. S. L. Aiello, S. Andreani, N. Avenia, G. Basili, C. Bellotti, D. Bettini, M. Biffoni, M. Bononi, et al.

    Intraoperative nerve monitoring (IONM) has been recognized as a useful adjunct into the field of thyroid and parathyroid surgery, aiding in the accurate identification and preservation of the recurrent laryngeal nerve (RLN), consequently reducing the probability of nerve injury and promoting surgical safety. This investigation seeks to amplify the findings of a similar nationwide survey performed in 2014 by offering an updated assessment of IONM practices among Italian surgical institutions, reflecting a decade of advancements and transformations in clinical approaches. A comprehensive nationwide survey was implemented targeting Italian endocrine surgeons to assess the prevalence, utilization patterns, attitudes and perceptions surrounding IONM in the context of thyroid and parathyroid surgical procedures. Structured questionnaires were administered to seventy endocrine surgery centers, and the resulting data were evaluated employing both quantitative and qualitative analysis methods. The survey disclosed that 67.14% of the participants confirmed the routine deployment of IONM across all cervical surgical procedures, particularly in high-risk contexts. Relative to the findings from 2014, a marked rise in the implementation of IONM has been recorded; however, variability persists, especially between continuous and intermittent monitoring strategies. Surgeons recognized improved surgical safety, decreased complication frequencies, and educational advantages as significant key drivers for the incorporation of IONM. Nonetheless, issues, such as false-positive and false-negative results, along with the lack of standardized protocols, remain barriers to its uniform application. During the past ten years, IONM has been thoroughly adopted by Italian endocrine surgeons as a result of its critical contribution to the improvement of surgical outcomes and the provision of educational resources. However, the results highlight the imperative for further standardization of protocols, the advancement of training programs, and the resolution of reimbursement obstacles to ensure equitable and consistent application of IONM across Italian centers, ultimately optimizing patient care.


  • Open Access

    How to Manage Advanced Differentiated Thyroid Cancer: Step-by-Step Analysis from Two Italian Tertiary Referral Centers

    by Paola Vincenza Sartori, Sara Andreani, Loredana De Pasquale, Iuliana Pauna, Antonio Mario Bulfamante, Paolo Salvatore Lorenzo Aiello, Rossella Melcarne, Laura Giacomelli, Marco Boniardi

    Background: Differentiated thyroid carcinoma (DTC) has an excellent prognosis; however, advanced disease is associated with a worse prognosis and is relatively common. Surgery followed by RAI treatment remains the mainstream treatment for a large majority of patients with high- and intermediate-risk DTC, but its benefits should be carefully weighed against the potential for harm. The aim of this paper is to critically review the experience in treating advanced DTC at two tertiary referral centers in Italy. Methods: Retrospective analysis of 300 patients who underwent surgery for ADTC over 30 years. Results: The complication rate was 50.33%. A total of 135 patients (45%) remained at regular follow-up, 118 (87.4%) were alive, while 17 (12.6%) were deceased. The mean overall survival at 12 years was 84.8% with a mean of 238 months. Eleven patients (8.1%) experienced a relapse after a median of 13 months. Conclusions: ADTC patients adequately treated can achieve prolonged survival even in the case of metastasis or disease relapse. Patients with ADTC should be referred to high-volume centers with the availability of an extended multidisciplinary team to receive tailored treatment.